open access

Ahead of print
Research paper (original)
Published online: 2021-10-15
Get Citation

Hilar cholangiocarcinoma – long-term results of radical and palliative treatment

Włodzimierz Otto1, Janusz Sierdziński2, Justyna Smaga1, Krzysztof Dudek1, Krzysztof Zieniewicz1
DOI: 10.5603/NJO.a2021.0063
Affiliations
  1. Dept. General, Transplant and Liver Surgery, University Medical Center, Medical University of Warsaw, Warsaw, Poland
  2. Dept. Medical Informatics and Telemedicine, University Medical Center, Medical University of Warsaw, Warsaw, Poland

open access

Ahead of print
Original article
Published online: 2021-10-15

Abstract

Introduction. Hilar cholangiocarcinoma (HC) is the tumor that requires multidisciplinary approach and treatment. The 3- and 5- year survivals of HC patients treated with surgery and palliative methods were evaluated in the study.

Material and methods. A study covered 368 patients treated between 2000–2014. Of them, 137 patients were categorized for surgery (RT group), and 231 for palliative treatment (PT group). The overall 3- and 5- year survivals were determined by the log rank test. Cox hazard regression model revealed the relative prognostic factors.

Results. The 3- and 5- year survival rates accounted for 38% and 21% after surgery, but 13% and 0 after palliative treatment (p < 0.0001). Radical tumor resection, negative lymph nodes, and early tumor T stage were the factors conducive to survival.

Conclusions. Surgery, if the radical tumor resection is possible, offers a chance for long-term survival. The positive effects of surgery treatment are lost against most of the majority of palliative patients

Abstract

Introduction. Hilar cholangiocarcinoma (HC) is the tumor that requires multidisciplinary approach and treatment. The 3- and 5- year survivals of HC patients treated with surgery and palliative methods were evaluated in the study.

Material and methods. A study covered 368 patients treated between 2000–2014. Of them, 137 patients were categorized for surgery (RT group), and 231 for palliative treatment (PT group). The overall 3- and 5- year survivals were determined by the log rank test. Cox hazard regression model revealed the relative prognostic factors.

Results. The 3- and 5- year survival rates accounted for 38% and 21% after surgery, but 13% and 0 after palliative treatment (p < 0.0001). Radical tumor resection, negative lymph nodes, and early tumor T stage were the factors conducive to survival.

Conclusions. Surgery, if the radical tumor resection is possible, offers a chance for long-term survival. The positive effects of surgery treatment are lost against most of the majority of palliative patients

Get Citation

Keywords

hilar cholangiocarcinoma; Bismuth-Corlette typing; T-stage typing; hemihepatectomy; negative resection margin

About this article
Title

Hilar cholangiocarcinoma – long-term results of radical and palliative treatment

Journal

Nowotwory. Journal of Oncology

Issue

Ahead of print

Article type

Research paper (original)

Published online

2021-10-15

DOI

10.5603/NJO.a2021.0063

Keywords

hilar cholangiocarcinoma
Bismuth-Corlette typing
T-stage typing
hemihepatectomy
negative resection margin

Authors

Włodzimierz Otto
Janusz Sierdziński
Justyna Smaga
Krzysztof Dudek
Krzysztof Zieniewicz

References (43)
  1. Sharma P, Yadav S. Demographics, tumor characteristics, treatment, and survival of patients with Klatskin tumors. Ann Gastroenterol. 2018; 31(2): 231–236.
  2. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992; 215(1): 31–38.
  3. Soares KC, Kamel I, Cosgrove DP, et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014; 3(1): 18–34.
  4. Launois B, Reding R, Lebeau G, et al. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg. 2000; 7(2): 128–134.
  5. Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol. 2005; 14(2): 59–74.
  6. Connor S, Barron E, Redhead DN, et al. Palliation for suspected unresectable hilar cholangiocarcinoma. Eur J Surg Oncol. 2007; 33(3): 341–345.
  7. Jarnagin W, Winston C. Hilar cholangiocarcinoma: diagnosis and staging. HPB (Oxford). 2005; 7(4): 244–251.
  8. Choi JY, Kim MJ, Lee JM, et al. Magnetic resonance cholangiography: comparison of two- and three-dimensional sequences for assessment of malignant biliary obstruction. Eur Radiol. 2008; 18(1): 78–86.
  9. Strongin A, Singh H, Eloubeidi MA, et al. Role of endoscopic ultrasonography in the evaluation of extrahepatic cholangiocarcinoma. Endosc Ultrasound. 2013; 2(2): 71–76.
  10. Aloia TA, Charnsangavej C, Faria S, et al. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg. 2007; 193(6): 702–706.
  11. Cannon RM, Brock G, Buell JF. Surgical resection for hilar cholangiocarcinoma: experience improves resectability. HPB (Oxford). 2012; 14(2): 142–149.
  12. de Jong MC, Marques H, Clary BM, et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer. 2012; 118(19): 4737–4747.
  13. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg. 1995; 130(3): 270–276.
  14. Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg. 2000; 7(2): 155–162.
  15. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999; 230(6): 808–18; discussion 819.
  16. Mansour J, Aloia T, Crane C, et al. Hilar Cholangiocarcinoma: expert consensus statement. HPB. 2015; 17(8): 691–699.
  17. Cho MS, Kim SH, Park SW, et al. Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg. 2012; 16(9): 1672–1679.
  18. Nuzzo G, Giuliante F, Ardito F, et al. Italian Chapter of the International Hepato-Pancreato-Biliary Association. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg. 2012; 147(1): 26–34.
  19. van Gulik TM, Ruys AT, Busch ORC, et al. Extent of liver resection for hilar cholangiocarcinoma (Klatskin tumor): how much is enough? Dig Surg. 2011; 28(2): 141–147.
  20. Zhang BH, Cheng QB, Luo XJ, et al. Surgical therapy for hiliar cholangiocarcinoma: analysis of 198 cases. Hepatobiliary Pancreat Dis Int. 2006; 5(2): 278–282.
  21. Baton O, Azoulay D, Adam DV, et al. Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes. J Am Coll Surg. 2007; 204(2): 250–260.
  22. Seyama Y, Kubota K, Sano K, et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg. 2003; 238(1): 73–83.
  23. Matull WR, Dhar DK, Ayaru L, et al. R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int. 2011; 31(1): 99–107.
  24. Eckel F, Schmid RM, Eckel F, et al. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007; 96(6): 896–902.
  25. Miao X, Pei D, Wen Yu, et al. Prognostic Value of Bismuth Typing and Modified T-stage in Hilar Cholangiocarcinoma. Cancer Translational Medicine. 2015; 1(1): 1.
  26. Rea DJ, Munoz-Juarez M, Farnell MB, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg. 2004; 139(5): 514–23; discussion 523.
  27. Cassani LS, Chouhan J, Chan C, et al. Biliary Decompression in Perihilar Cholangiocarcinoma Improves Survival: A Single-Center Retrospective Analysis. Dig Dis Sci. 2019; 64(2): 561–569.
  28. Teng F, Xian YT, Lin J, et al. Comparison of Unilateral With Bilateral Metal Stenting for Malignant Hilar Biliary Obstruction. Surg Laparosc Endosc Percutan Tech. 2019; 29(1): 43–48.
  29. Mansfield SD, Barakat O, Charnley RM, et al. Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome. World J Gastroenterol. 2005; 11(48): 7625–7630.
  30. Zheng-Rong L, Hai-Bo Y, Xin C, et al. Resection and drainage of hilar cholangiocarcinoma: an 11-year experience of a single center in mainland China. Am Surg. 2011; 77(5): 627–633.
  31. Szymańska D, Durczyński A, Strzelczyk J. Hepatico-jejunostomia obwodowa; alternatywna metoda leczenia paliatywnego nieresekcyjnych guzów wnęki Wątroby. Doniesienie wstępne. Nowotwory J Oncology. 2009; 70(2): 188–193.
  32. Lampe P, Jabłońska B. Surgical treatment of cholangiocarcinoma. Postępy Nauk Medycznych. 2011; 1: 16–22.
  33. Palczewski P, Cieszanowski A, Gołębiowski M. State of the art imagine of Klatskin tumor. Polish J Radiology. 2005; 70(2): 69–77.
  34. Janczak D, Wierasko A, Kabziński P, et al. Implantation of plastic and metal stents to biliary tract in obstructive jaundice in material of Surgery Department of 4th Military Clinical Hospital in Wroclaw. Polim Med. 2013; 43(1): 5–9.
  35. Jeziorski KG. Współczesne możliwości chemioterapii nowotworów złośliwych wątroby i dróg żółciowych zewnątrzwątrobowych. Nowotwory J Oncology. 2007; 52(1): 9–13.
  36. Jassem J, Duchnowska R, Kawecki A, et al. Post-treatment surveillance in most common solid malignancies in adults. Nowotwory J Oncology. 2014; 64(5): 415–435.
  37. Jo HS, Kim DS, Yu YD, et al. Right-side versus left-side hepatectomy for the treatment of hilar cholangiocarcinoma: a comparative study. World J Surg Oncol. 2020; 18(1): 3.
  38. Lidsky ME, Jarnagin WR. Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center. Ann Gastroenterol Surg. 2018; 2(4): 304–312.
  39. Nickloes T, Reed B, Mack LaMar O. Bile duct tumors: Treatment & management. Medscape, Drugs & Diseases. In: General Surgery 2020. Updated: Apr 20.
  40. Dondossola D, Ghidini M, Grossi F, et al. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol. 2020; 26(25): 3542–3561.
  41. Mizuno T, Ebata T, Nagino M. Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches. Surg Oncol. 2020; 33: 201–206.
  42. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9): 557–588.
  43. Ivanisova N, Solovey A. Klatskin tumor: treatment of bile duct cancer in Germany. Booking Health GmbH > Diagnosis & treatment 2021. https://bookinghealth.com.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl